Hidehito HORINOUCHI
hhorinouchi.bsky.social
Medical Oncologist, NCC Japan, JCOG Lung Cancer Study Group, Education committee of JSMO, JLCS, @iaslc.bsky.social. @ascocancer.bsky.social FCOI http://bit.ly/3DBhVGE
👤 Joined on 11 November 2024
134
Followers
37
Following
139
Total Posts
📜 Kullanıcı Geçmişi
- 11 Kas 2024, 16:09
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@hhorinouchi.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
In NSCLC with 𝘌𝘎𝘍𝘙 exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. Full phase 3 WU-KONG28 trial results: https://nej.md/4fQWMwa #ASCO26
Show Post
10 Must-Read Posts in Immuno-Oncology This Week @elisabettabonzano.bsky.social @stephenvliu.bsky.social @arndtvogel.bsky.social @hhorinouchi.bsky.social oncodaily.com/oncolibrary/... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmunoOncology
Show Post
“Students have come up to me to say, ‘I’m studying cancer research because of this review. I feel like a rock star.” 🧪 These are the 25 most-cited papers published this century https://go.nature.com/4ilZw2q
Show Post
Full support to Alex Adjei for President-Elect in 2025 #IASLC Board of Directors Election! I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations. @iaslc.bsky.social
Show Post
Here, Nakagawa et al. report the final OS outcomes for the intention-to-treat population in the double-blind, placebo-controlled phase 3 RELAY study. Read More here ➡️ bit.ly/42EEp5J
Show Post